111 related articles for article (PubMed ID: 8911678)
1. Norepinephrine loss selectively enhances chronic nigrostriatal dopamine depletion in mice and rats.
Fornai F; Torracca MT; Bassi L; D'Errigo DA; Scalori V; Corsini GU
Brain Res; 1996 Oct; 735(2):349-53. PubMed ID: 8911678
[TBL] [Abstract][Full Text] [Related]
2. Noradrenergic modulation of methamphetamine-induced striatal dopamine depletion.
Fornai F; Alessandrì MG; Torracca MT; Bassi L; Scalori V; Corsini GU
Ann N Y Acad Sci; 1998 May; 844():166-77. PubMed ID: 9668674
[TBL] [Abstract][Full Text] [Related]
3. Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice.
Fornai F; Bassi L; Torracca MT; Scalori V; Corsini GU
Eur J Pharmacol; 1995 Sep; 283(1-3):99-102. PubMed ID: 7498327
[TBL] [Abstract][Full Text] [Related]
4. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice.
Marien M; Briley M; Colpaert F
Eur J Pharmacol; 1993 Jun; 236(3):487-9. PubMed ID: 7689466
[TBL] [Abstract][Full Text] [Related]
5. Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine losses.
Fornai F; Giorgi FS; Alessandrì MG; Giusiani M; Corsini GU
J Neurochem; 1999 Feb; 72(2):777-84. PubMed ID: 9930753
[TBL] [Abstract][Full Text] [Related]
6. Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: a microdialysis study.
Lategan AJ; Marien MR; Colpaert FC
Life Sci; 1992; 50(14):995-9. PubMed ID: 1372673
[TBL] [Abstract][Full Text] [Related]
7. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions.
Fornai F; Alessandrì MG; Torracca MT; Bassi L; Corsini GU
J Pharmacol Exp Ther; 1997 Oct; 283(1):100-7. PubMed ID: 9336313
[TBL] [Abstract][Full Text] [Related]
8. Noradrenergic Modulation of Methamphetamine-Induced Striatal Dopamine Depletion.
Fornai F; Alessandrì MG; Torrac MT; Bassi L; Scalori V; Corsini GU
Ann N Y Acad Sci; 1998 May; 844(1):166-177. PubMed ID: 29090815
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity.
Bourque M; Liu B; Dluzen DE; Di Paolo T
Biochem Pharmacol; 2007 Nov; 74(9):1413-23. PubMed ID: 17825264
[TBL] [Abstract][Full Text] [Related]
10. Genetic or pharmacological blockade of noradrenaline synthesis enhances the neurochemical, behavioral, and neurotoxic effects of methamphetamine.
Weinshenker D; Ferrucci M; Busceti CL; Biagioni F; Lazzeri G; Liles LC; Lenzi P; Pasquali L; Murri L; Paparelli A; Fornai F
J Neurochem; 2008 Apr; 105(2):471-83. PubMed ID: 18042179
[TBL] [Abstract][Full Text] [Related]
11. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine.
Wagner GC; Ricaurte GA; Seiden LS; Schuster CR; Miller RJ; Westley J
Brain Res; 1980 Jan; 181(1):151-60. PubMed ID: 7350950
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system.
Gao X; Dluzen DE
Neuroscience; 2001; 103(2):385-94. PubMed ID: 11246153
[TBL] [Abstract][Full Text] [Related]
13. Epothilone D prevents binge methamphetamine-mediated loss of striatal dopaminergic markers.
Killinger BA; Moszczynska A
J Neurochem; 2016 Feb; 136(3):510-25. PubMed ID: 26465779
[TBL] [Abstract][Full Text] [Related]
14. Benzamide, an inhibitor of poly(ADP-ribose) polymerase, attenuates methamphetamine-induced dopamine neurotoxicity in the C57B1/6N mouse.
Cosi C; Chopin P; Marien M
Brain Res; 1996 Oct; 735(2):343-8. PubMed ID: 8911677
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/- BDNF mutant mice.
Dluzen DE; Gao X; Story GM; Anderson LI; Kucera J; Walro JM
Exp Neurol; 2001 Jul; 170(1):121-8. PubMed ID: 11421589
[TBL] [Abstract][Full Text] [Related]
16. Noradrenaline loss selectivity exacerbates nigrostriatal toxicity in different species of rodents.
Fornai F; Bassi L; Bonaccorsi I; Giorgi F; Corsini GU
Funct Neurol; 1997; 12(3-4):193-8. PubMed ID: 9218976
[No Abstract] [Full Text] [Related]
17. Blockade of tachykinin NK1 receptors by CP-96345 enhances dopamine release and the striatal dopamine effects of methamphetamine in rats.
Gygi SP; Gibb JW; Johnson M; Hanson GR
Eur J Pharmacol; 1993 Nov; 250(1):177-80. PubMed ID: 7509751
[TBL] [Abstract][Full Text] [Related]
18. Apomorphine-induced alterations in striatal and substantia nigra pars reticulata glutamate following unilateral loss of striatal dopamine.
Touchon JC; Holmer HK; Moore C; McKee BL; Frederickson J; Meshul CK
Exp Neurol; 2005 May; 193(1):131-40. PubMed ID: 15817272
[TBL] [Abstract][Full Text] [Related]
19. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
20. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
Zuddas A; Fascetti F; Corsini GU; Piccardi MP
Exp Neurol; 1994 May; 127(1):54-61. PubMed ID: 8200437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
